Trial document
DRKS00003551
Trial Description
Title
graft function adapted tacrolimus therapy after liver transplantation (GRAFTT)
Trial Acronym
GRAFTT
URL of the Trial
http://www.charite.de/avt/forschung/workgroup_for_the_liver/ongoing-projects.html#GRAFTT
Brief Summary in Lay Language
Tacrolimus is an important standard induction and maintenance immunosuppressant drug after liver transplantation (LT). Nevertheless, tacrolimus has a narrow therapeutic window and can cause serious adverse effects. Acute overdosing can provoke renal failure and severe neurological disorders, On the other hand, insufficient levels could lead to graft rejection in the initial post-transplant phase.
The purpose of the study is to improve immunosuppressive therapy until three days after liver transplantation.
Patients receiving primary orthotopic LT will be enrolled in this study.
The aim of this study is to achieve a reduced number of patients suffering from toxic drug reactions or organ rejection.
Our assumption is that medication adaption for real liver function improves graft survival.
Therefore the real liver function is measured after liver transplantation. The dosage of tacrolimus will be adapted on this measured liver function. The measument will be repeated on first day after liver transplantation.
Brief Summary in Scientific Language
Prospective,randomized, controlled open label trial with Prograf® and Advagraf® (GRAFTT)
Do you plan to share individual participant data with other researchers?
[---]*
Description IPD sharing plan:
[---]*
Organizational Data
- DRKS00003551
- 2013/05/31
- 2011/12/05
- yes
- Approved
- 11/0560-ZS EK 11, Ethik-Kommission des Landes Berlin
Secondary IDs
- 2011-004944-23
- EUCTR2011-004944-23-DE (EUCTR)
- 4037842
Health Condition or Problem studied
- livertransplantation
- K72.9 - Hepatic failure, unspecified
Interventions/Observational Groups
-
Prograf®, with liver function adapted TAC-regime in the first three days after LTx, twice a day, 0,025- 0,1 mg/kg body weight
-
Advagraf®, with liver fuction adapted TAC-regime, in the first three days after LTx, once a day, 0,05- 0,2 mg/kg body weight
-
control group with standard tacrolimus regime (Prograf), in the first three days after LTx, twice a day, 0,05 mg/kg body weight
Characteristics
- Interventional
- [---]*
- Randomized controlled trial
- Open (masking not used)
- [---]*
- Active control
- Treatment
- Parallel
- IV
- No
Primary Outcome
Number of patients suffering from either toxic or insufficient tacrolimus whole blood trough levels during the initial 14 days after liver transplantation
(twice levels of <5 ng/mL during post-transplant days 1-14 or one levels >20 ng/mL during post-transplant days 1-14)
Secondary Outcome
1.) Tacrolimus whole blood trough level during post-transplant days 1-14
2.) Total cumulative incidence of inadequate tacrolimus whole blood trough levels during post-transplant days 1-14 (<5 ng/mL or >20 ng/mL)
3.) Creatinine serum levels (day 1-14 after transplantation)
4.) Incidence of Adverse effects:
a.) acute renal failure (days 1-14)
b.) chronic renal insufficiency (until 1 year after transplantation)
c) Neurological effects including
encephalopathy, seizures or coma (days 1- 14)
5.) graft rejection (time frame: 1 year)
6.) Rejection free time interval (time frame: 1 year)
7.) Assessment of graft and patient survival (time frame: 1 year)
Countries of Recruitment
- Germany
Locations of Recruitment
- University Medical Center
- University Medical Center
- University Medical Center
- University Medical Center
Recruitment
- Actual
- 2012/07/26
- 210
- Multicenter trial
- National
Inclusion Criteria
- Both, male and female
- 18 Years
- no maximum age
Additional Inclusion Criteria
Inclusion criteria
-Patients intended for orthotopic deceased-
donor LT
- Recipient age ≥18 yrs.
- Capability to understand the purpose and
the risk of the study
- Written informed consent prior LT
Exclusion Criteria
- Participation in other clinical trials during <28 days before LT
- any organ transplantation before enrollment, High-urgent transplantation, split liver LT, living donor LT, combined multi-organ transplantation, AB0 incompatible grafts, retransplantation
- Recipients with malignant tumors beside HCC respecting the Milan criteria or liver metastasis
-Target trough levels of tacrolimus differing from 10-15 ng/mL in the first 14 days after LTx)
- planned use of other immunosuppressive drugs including ciclosporine A, sirolimus, everolimus, azathioprine in the first 14 days after LTx
- patients with known intolerance of tacrolimus
- patients with a history of substance or drug abuse
- patients with psychiatric disorders or any forms of substance abuse not capable of understanding the purpose and risks of the study
- subjects known to be HIV positive- pregnant woman or breastfeeding mother
Addresses
-
start of 1:1-Block address primary-sponsor
- Charité Universitätsmedizin Berlin
- Augustenburger Platz 1
- 13353 Berlin
- Germany
end of 1:1-Block address primary-sponsorstart of 1:1-Block address contact primary-sponsor- 030 450 552 001
- 030 450 552 927
- martin.stockmann at charite.de
- http://www.charite.de
end of 1:1-Block address contact primary-sponsor -
start of 1:1-Block address scientific-contact
- Charité Campus Virchow-Klinikum
- Mr. Priv.-Doz. Martin Stockmann
- Augustenburger Platz 1
- 13353 Berlin
- Germany
end of 1:1-Block address scientific-contactstart of 1:1-Block address contact scientific-contact- 030/ 450 552 001
- 030/ 450 552 927
- martin.stockmann at charite.de
- http://www.charite.de
end of 1:1-Block address contact scientific-contact -
start of 1:1-Block address public-contact
- Charité Universitätsmedizin Berlin
- Priv.-Doz. Martin Stockmann
- Augustenburger Platz 1
- 13353 Berlin
- Germany
end of 1:1-Block address public-contactstart of 1:1-Block address contact public-contact- 030 450 552 001
- 030 450 552 927
- martin.stockmann at charite.de
- http://www.charite.de
end of 1:1-Block address contact public-contact
Sources of Monetary or Material Support
-
start of 1:1-Block address materialSupport
- Charité Campus Virchow-Klinikum
- Augustenburger Platz 1
- 13353 Berlin
- Germany
end of 1:1-Block address materialSupportstart of 1:1-Block address contact materialSupport- [---]*
- [---]*
- [---]*
- http://www.charite.de
end of 1:1-Block address contact materialSupport -
start of 1:1-Block address otherSupport
- Astellas Pharma GmbH
- Georg-Brauchle- Ring
- 80992 München
- Germany
end of 1:1-Block address otherSupportstart of 1:1-Block address contact otherSupport- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact otherSupport
Status
- Recruiting ongoing
- [---]*
Trial Publications, Results and other Documents
- [---]*